NCT01635686

Brief Summary

The purpose of this study was to compare the safety and pharmacokinetic characteristics of DWP422 25 mg with those of ENBREL 25MG PFS INJ. after subcutaneous injection in healthy male volunteers.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
38

participants targeted

Target at P50-P75 for phase_1 rheumatoid-arthritis

Timeline
Completed

Started Sep 2012

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 4, 2012

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 9, 2012

Completed
2 months until next milestone

Study Start

First participant enrolled

September 1, 2012

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
Last Updated

July 26, 2012

Status Verified

July 1, 2012

Enrollment Period

9 months

First QC Date

July 4, 2012

Last Update Submit

July 25, 2012

Conditions

Outcome Measures

Primary Outcomes (1)

  • Etanercept levels in blood

Study Arms (2)

DWP422

EXPERIMENTAL
Drug: DWP422 25mg

ENBREL

ACTIVE COMPARATOR
Drug: ENBREL 25MG PFS INJ.

Interventions

Eligibility Criteria

Age20 Years - 45 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy males, 20 to 45 years of age the moment of screening
  • Body mass index is between 19.0 and 27.0 kg/m2

You may not qualify if:

  • Hypersensitivity response to the experimental and comparator drugs
  • The tuberculosis patient or latent tuberculosis patient

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Hospital

Seoul, South Korea

Location

MeSH Terms

Conditions

Arthritis, Rheumatoid

Interventions

Etanercept

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Intervention Hierarchy (Ancestors)

Immunoglobulin Fc FragmentsImmunoglobulin FragmentsPeptide FragmentsPeptidesAmino Acids, Peptides, and ProteinsImmunoglobulin Constant RegionsImmunoglobulinsImmunoproteinsBlood ProteinsProteinsSerum GlobulinsGlobulinsReceptors, Tumor Necrosis FactorReceptors, CytokineReceptors, ImmunologicReceptors, Cell SurfaceMembrane Proteins

Central Study Contacts

Kyung-Sang Yu

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 4, 2012

First Posted

July 9, 2012

Study Start

September 1, 2012

Primary Completion

June 1, 2013

Study Completion

June 1, 2013

Last Updated

July 26, 2012

Record last verified: 2012-07

Locations